EarningsQ2 2026 Earnings Report
DE:PBDA Q2 2026 EPS Results
Actual EPS€0.04
Consensus EPS>-€0.01
Beat/MissBeat by +€0.05
One Year Ago EPS€0.00
DE:PBDA Q2 2026 Revenue Results
Actual Revenue€17.70M
Expected Revenue€11.52M
Beat/MissBeat by +€6.18M
YoY Revenue Growth+27.07%
Earnings Announcement Details
QuarterQ2 2026
Date08/12/2026
TimeBefore Open
Conference CallWednesday, August 12, 2026
DE:PBDA Upcoming Earnings
Protalix's next earnings date is estimated for November 16, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:PBDA Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented several strong operational and financial positives — double-digit quarterly revenue growth, a >100% year-to-date revenue increase, meaningful Q2 net income, strong Elfabrio commercial momentum with regulatory and patent tailwinds, a solid cash position and advancing pipeline (PRX-115 with topline expected H2 2027). Offsetting risks include quarter-to-quarter revenue lumpiness and partner concentration (Chiesi), a reliance on a one-time $25M milestone in H1, increased cost of revenues and taxes, and clinical uncertainties around immunogenicity and regimen selection for PRX-115. Overall, the positives — particularly the robust revenue growth, improved profitability and cash position — outweigh the noted risks, though sustainability and immunogenicity remain items to monitor.Company Guidance
Quarterly Revenue Growth
Total revenues for Q2 2026 were $19.9M versus $15.7M in Q2 2025, an increase of $4.2M (+26.8%).
Strong Year-to-Date Revenue Increase
First half 2026 revenues were $53.6M versus $25.8M in H1 2025, an increase of $27.8M (+107.8%), driven by Elfabrio sales and a $25M Chiesi milestone recognized in Q1.
Elfabrio Commercial Momentum
Elfabrio sales through partner Chiesi drove growth (Q2 selling goods $19.8M vs $15.4M, +$4.4M/+28.6%), with new geographic approvals (e.g., South Korea) and a European approval for once-every-4-weeks dosing strengthening market penetration.
Profitability Improvement
Net income for Q2 2026 was $3.8M ($0.05 per share) versus $0.164M in Q2 2025 — a material improvement in profitability compared with the prior year quarter.
Lower R&D Expense (Near-Term Benefit)
R&D expenses declined to $4.4M in Q2 2026 from $6.0M in Q2 2025, a decrease of $1.6M (-26.7%), primarily due to a $2.1M reduction recognized under the new R&D law (ongoing grant availability).
Solid Liquidity and Balance Sheet
Cash, cash equivalents and short-term bank deposits totaled $40.7M as of June 30, 2026; the company reported no outstanding debt or warrants, providing financial flexibility to support operations and pipeline advancement.
Clinical and Pipeline Progress
PRX-115 (long-acting uricase) is advancing as planned with a multiple-dose Phase 2 (RELEASE) underway; topline results expected in H2 2027 and enrollment expected to complete by year-end 2026 (target ~5 months).
Large Addressable Market Opportunity
Management cites a projected global Fabry market of ~$3.2B by 2031 and positions Elfabrio to capture 15%–20% of that market (implying potential revenues of ~$480M–$640M at full capture).
DE:PBDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed